

Special Issue

Microbial Antigen Identification and Vaccine Delivery Systems

Message from the Guest Editors

Vaccine efficacy and immunogenicity depend on the host, pathogen, and pathogenesis of the disease. The optimization of vaccine efficacy is therefore a requirement of many vaccines, including approved ones. Key aspects of vaccine design and development involve the identification of the foremost immunogenic determinants of a pathogen and the choice of the best delivery system. Different vaccine delivery systems, using the same antigen, can induce variable outcomes. In this Special Issue, we invite articles focused on innovative methods for immunogenic determinants identification from microbial pathogens and the optimization of microbial delivery systems to improve vaccine efficacy and immunogenicity. We welcome all types of manuscripts accepted in the journal, with a special focus in immunogenic determinant identification, irrespective of their biochemical nature and antigen presentation. Given that the efficacy of a vaccine antigen depends greatly on the delivery method, this Special Issue will also focus on improving microbial-based delivery systems.

Guest Editors

Dr. Jorge H. Leitão

Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal

Dr. Paulo Bettencourt

Centro de Investigação Interdisciplinar em Saúde, Faculdade de Medicina, Universidade Católica Portuguesa, 2625-631 Rio de Mouro, Portugal

Deadline for manuscript submissions

closed (31 July 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/63634

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).